|1||NCT00579683||Completed||Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer||
||228||All||Child, Adult, Senior||NCT00579683||04-103||August 2004||February 2016||February 2016||December 24, 2007||February 4, 2016||
|2||NCT03133546||Recruiting||Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER)||
||Other / Industry||
||154||All||18 Years and older (Adult, Senior)||NCT03133546||ETOP 10-16
|BOOSTER||May 31, 2017||May 2022||May 2022||April 28, 2017||February 20, 2018||
† Study has passed its completion date and status has not been verified in more than two years.